DOUCEFONTE — Instant downloads, pay with Bitcoin

At a glance

Wakefulness / shift-work alertness

Cognitive performance (memory, processing)

Low abuse / dependence liability

Fatigue reduction (adjunct use)

Serious skin / hypersensitivity reaction

Blood pressure / cardiovascular

Sleep disruption (late dosing)

Drug interactions (CYP3A4/2C19)

BenefitSide effectHealth risk· more & brighter bars = stronger

Effects

Sustained wakefulness: Significantly extends time awake and reduces excessive daytime sleepiness; proven in narcolepsy, shift-work disorder, and obstructive sleep apnea adjunct treatment ^[1].
Cognitive enhancement: Improves working memory, episodic memory, processing speed, and verbal learning at well-tolerated doses in healthy adults and clinical populations ^[6].
Reduced sleep-deprivation impairment: Suppresses microsleeps and reduces cognitive impairment caused by sleep loss, with shorter required recovery sleep compared with placebo ^[7].
Low abuse/dependence liability: Unlike amphetamines or methylphenidate, modafinil shows low abuse potential, no significant withdrawal symptoms on cessation, and no rebound phenomena in clinical trials ^[8]^[9].
Mood / fatigue benefit: Off-label evidence supports use in treatment-resistant depression, fatigue in multiple sclerosis, and cancer-related fatigue as an adjunct agent ^[6].

Classification

Wakefulness-promoting agent (eugeroic) / Schedule IV CNS agent

Active half-life

~15 hours (after multiple doses)

Route

Oral (tablet)

Onset

Peak plasma ~2–4 hours post-dose

Schedule

US Schedule IV (C-IV), Rx-only

Risks & side effects

Most important: The most serious risk is a potentially life-threatening hypersensitivity reaction — including Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis, anaphylaxis, and multi-organ hypersensitivity — which, though rare, has required hospitalisation in post-marketing reports ^[10]^[11]. Stop modafinil immediately and seek emergency care at the first sign of rash, facial swelling, or difficulty breathing ^[10].

Common

Headache (most frequently reported adverse effect, occurring significantly more than placebo in clinical trials) ^[8]
Nausea / GI upset ^[8]
Insomnia / difficulty initiating sleep — especially with late dosing ^[12]
Anxiety or nervousness (~5–7%) ^[12]
Dizziness (~5%) ^[12]
Dry mouth (~4%), loss of appetite (~4%) ^[12]
Diarrhoea (~6%) ^[12]

Serious

Hypertension — blood pressure elevation reported in ~3% of users; monitor regularly ^[12]^[13]
Cardiac palpitations / tachycardia — reported in ~2% of users ^[12]
Psychiatric effects — agitation, mood swings, or (rarely) mania; use with caution in bipolar disorder ^[14]
Hepatic impairment — clearance is significantly reduced; dose reduction required; avoid in severe hepatic disease ^[15]
Renal impairment — metabolite accumulation (modafinil acid increases ~9-fold) in severe chronic kidney disease ^[15]

Rare

Stevens-Johnson Syndrome / toxic epidermal necrolysis — post-marketing cases requiring hospitalisation ^[10]^[11]
Anaphylaxis / angioedema — life-threatening; discontinue immediately ^[10]^[11]
Multi-organ hypersensitivity reaction (DRESS-like) ^[10]
Cyclosporine blood level reduction — one case report of ~50% drop in cyclosporine levels after one month of modafinil ^[15]

Safety & harm reduction

Who must not use it

Known hypersensitivity to modafinil or armodafinil — risk of life-threatening SJS, anaphylaxis, or DRESS ^[10]
Severe hepatic impairment — reduced clearance leads to significantly elevated plasma levels; contraindicated or requires major dose reduction ^[15]
Children and adolescents — not approved for any indication in paediatric patients ^[11]
Pregnancy — consult physician; enrol in pregnancy registry if modafinil is taken during pregnancy ^[13]

Monitoring

Blood pressure — check more frequently during treatment, especially in patients with pre-existing hypertension ^[13]
Liver function — modafinil is primarily hepatically metabolised; monitor in patients with hepatic impairment ^[15]
Renal function — metabolite (modafinil acid) accumulates ~9-fold in severe CKD; adjust accordingly ^[15]
Psychiatric status — monitor for emergence or worsening of anxiety, mania, or mood symptoms ^[14]
Skin — inspect at each visit; stop immediately and seek care if any rash appears ^[10]

Interactions

Hormonal contraceptives (pills, patches, implants, rings, injections, IUDs) — modafinil induces CYP3A4 and reduces contraceptive efficacy; use an alternative non-hormonal method during treatment and for 1 month after stopping ^[11]^[15]
Cyclosporine — modafinil may reduce cyclosporine blood levels by ~50% via CYP3A4 induction; monitor cyclosporine levels closely ^[15]
Triazolam / midazolam (CYP3A4 substrates) — modafinil reduces Cmax and AUC; dose adjustment may be required ^[15]
CYP2C19 substrates (e.g. omeprazole, phenytoin, diazepam, propranolol, TCAs) — modafinil inhibits CYP2C19; plasma levels of these drugs may increase ^[11]
Alcohol — interaction unknown; avoid concomitant use ^[11]
MAOIs — insufficient data; exercise caution ^[14]
Warfarin — monitor prothrombin time / INR when co-administered ^[14]

Protocols

Take as a single morning dose to minimise sleep disruption given the ~15-hour half-life ^[15]
For shift-work sleep disorder, take approximately 1 hour before the start of the work shift ^[1]
Do not increase dose without medical review if wakefulness effect is perceived as insufficient ^[13]
Avoid driving or operating heavy machinery until individual response is established — modafinil does not fully correct impaired judgment in all users ^[11]
Switch to reliable non-hormonal contraception during treatment and for at least 1 month post-cessation ^[11]

Dosage context

Commonly reported clinical doses are 200 mg/day as a single morning dose for narcolepsy and obstructive sleep apnea adjunct therapy ^[16]. Doses up to 400 mg/day as a single dose have been well tolerated, but there is no consistent evidence that 400 mg provides additional wakefulness benefit beyond 200 mg/day ^[16]. Pharmacokinetics are dose-independent (linear) across 200–600 mg/day ^[17]. These are FDA-label clinical doses, not a prescription or endorsement for off-label use.

Sources

This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.

At a glance

Effects

Product specifics

What it is

How it works

Risks & side effects

Safety & harm reduction

Dosage context

Sources

Substance reviews(21)